NO20004350D0 - Preparat med vedvarende frigivinng av AII-antagonist, fremstilling og anvendelse herav - Google Patents

Preparat med vedvarende frigivinng av AII-antagonist, fremstilling og anvendelse herav

Info

Publication number
NO20004350D0
NO20004350D0 NO20004350A NO20004350A NO20004350D0 NO 20004350 D0 NO20004350 D0 NO 20004350D0 NO 20004350 A NO20004350 A NO 20004350A NO 20004350 A NO20004350 A NO 20004350A NO 20004350 D0 NO20004350 D0 NO 20004350D0
Authority
NO
Norway
Prior art keywords
preparation
sustained release
aii antagonist
angiotensin
antagonistic activity
Prior art date
Application number
NO20004350A
Other languages
English (en)
Other versions
NO20004350L (no
Inventor
Yasutaka Igari
Akira Saikawa
Yoshiyuki Inada
Shigeru Kamei
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of NO20004350D0 publication Critical patent/NO20004350D0/no
Publication of NO20004350L publication Critical patent/NO20004350L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1611Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20004350A 1998-03-04 2000-09-01 Preparat med vedvarende frigivinng av AII-antagonist, fremstilling og anvendelse herav NO20004350L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP5236698 1998-03-04
PCT/JP1999/001011 WO1999044590A1 (en) 1998-03-04 1999-03-03 Sustained-release preparation for aii antagonist, production and use thereof

Publications (2)

Publication Number Publication Date
NO20004350D0 true NO20004350D0 (no) 2000-09-01
NO20004350L NO20004350L (no) 2000-10-03

Family

ID=12912818

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004350A NO20004350L (no) 1998-03-04 2000-09-01 Preparat med vedvarende frigivinng av AII-antagonist, fremstilling og anvendelse herav

Country Status (21)

Country Link
US (2) US6589547B1 (no)
EP (1) EP1058541B1 (no)
KR (1) KR20010086245A (no)
CN (1) CN1291888A (no)
AT (1) ATE258430T1 (no)
AU (1) AU2745199A (no)
BR (1) BR9908474A (no)
CA (1) CA2318446C (no)
DE (1) DE69914460T2 (no)
EE (1) EE200000499A (no)
ES (1) ES2214013T3 (no)
HU (1) HUP0101439A3 (no)
ID (1) ID25640A (no)
IL (1) IL137979A0 (no)
LT (1) LT4800B (no)
LV (1) LV12585B (no)
NO (1) NO20004350L (no)
PL (1) PL342684A1 (no)
SK (1) SK11902000A3 (no)
WO (1) WO1999044590A1 (no)
ZA (1) ZA991706B (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL137979A0 (en) * 1998-03-04 2001-10-31 Takeda Chemical Industries Ltd Production, release preparation for aii antagonist-sustained and use thereof
WO2000066161A1 (fr) 1999-04-28 2000-11-09 Takeda Chemical Industries, Ltd. Preventifs / remedes / inhibiteurs de progression pour retinopathie simplex ou retinopathie preproliferante
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
WO2001060362A1 (en) * 2000-02-18 2001-08-23 Takeda Chemical Industries, Ltd. TNF-α INHIBITORS
AU2001232348A1 (en) * 2000-02-21 2001-08-27 Takeda Chemical Industries Ltd. Sustained release preparations of physiologically active compound hardly solublein water and production process and use of the same
WO2002015935A1 (fr) * 2000-08-25 2002-02-28 Takeda Chemical Industries, Ltd. Agents de reduction du fibrinogene
US20040102502A1 (en) * 2000-10-25 2004-05-27 Toshifumi Watanabe Preventing/remedies for portal hypertension
WO2002074340A1 (fr) * 2001-03-16 2002-09-26 Takeda Chemical Industries, Ltd. Procede de fabrication d'une preparation a liberation continue
US20040219208A1 (en) * 2001-08-03 2004-11-04 Ryu Kawamura Sustained-release medicines
BRPI0105509B8 (pt) * 2001-11-05 2021-05-25 Univ Minas Gerais formulações do peptídeo angiotensina-(1-7) usando as ciclodextrinas, lipossomas e o polímero plga
WO2003041739A1 (en) 2001-11-13 2003-05-22 Takeda Chemical Industries, Ltd. Anticaner agents
AU2002349673A1 (en) * 2001-12-03 2003-06-17 Takeda Chemical Industries, Ltd. Insulin resistance improving agents
US7407778B2 (en) * 2002-02-07 2008-08-05 Pettegrew Jay W Compounds, compositions and methods for treating neuropsychiatric disorders
US7700074B2 (en) * 2002-02-07 2010-04-20 Pettegrew Jay W Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism
KR101092279B1 (ko) * 2002-12-27 2011-12-13 다케다 야쿠힌 고교 가부시키가이샤 체중 증가 억제제
US20050038093A1 (en) * 2003-05-02 2005-02-17 Boehringer Ingelheim International Gmbh Treating diabetic retinopathy with angiotensin II receptor blockers
US20060257842A1 (en) * 2003-05-29 2006-11-16 Pettegrew Jay W Cryopreservation media and molecules
CN1795198B (zh) * 2003-05-29 2011-08-17 杰伊·W·佩特格尤 对神经精神疾病进行医学成像所用的甘油磷酸胆碱及其衍生物
WO2005097109A1 (en) * 2004-04-01 2005-10-20 Daniel Batlle Methods for achieving a protective ace2 expression level
DE602005025755D1 (de) 2004-06-04 2011-02-17 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
AU2005290394A1 (en) * 2004-10-07 2006-04-13 Takeda Pharmaceutical Company Limited Agent for prophylaxis or treatment of metabolic syndrome
US8022086B2 (en) * 2004-10-29 2011-09-20 Kowa Co., Ltd. Therapeutic agent for glomerular disease
EP1850835A1 (fr) * 2005-02-21 2007-11-07 Flamel Technologies Forme pharmaceutique orale de losartan
GEP20115138B (en) * 2005-03-30 2011-01-10 Takeda Pharmaceuticals Co Benzimidazole derivative and use as angiotensin ii antagonist
KR20080039510A (ko) * 2005-08-22 2008-05-07 알렘빅 리미티드 발사르탄 제조 방법
ZA200901075B (en) * 2006-08-10 2010-05-26 Takeda Pharmaceutical Pharmaceutical composition
PE20081364A1 (es) * 2006-09-04 2008-12-04 Novartis Ag Composicion farmaceutica que comprende valsartan
EP1897537A1 (en) * 2006-09-04 2008-03-12 Novartis AG Composition comprising an angiotensin II receptor antagonist
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
CL2007003658A1 (es) 2006-12-18 2008-05-09 Takeda Pharmaceutical Composicion de liberacion sostenida que comprende un peptido; procedimiento para preparar dicha composicion; agente profilactico o terapeutico para cancer de prostata, hiperplasia prostatica, endometriosis, fibroide uterino, fibroma uterino, pubertad
CN101011393B (zh) * 2007-02-16 2010-10-06 广州柏赛罗药业有限公司 厄贝沙坦胃内滞留型缓释药物组合物
AU2008235790B2 (en) * 2007-03-28 2013-06-06 Takeda Pharmaceutical Company Limited Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent
WO2009134057A2 (ko) * 2008-04-29 2009-11-05 한올제약주식회사 안지오텐신-ⅱ-수용체 차단제를 포함하는 약제학적 제제
CA2761576C (en) 2009-05-20 2017-08-22 Boehringer Ingelheim Vetmedica Gmbh Oral suspension comprising telmisartan
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2751907A (en) * 1953-09-18 1956-06-26 Bishop & Co Platinum Works J Pellet injector
JPS5671073A (en) 1979-11-12 1981-06-13 Takeda Chem Ind Ltd Imidazole derivative
JPS5671074A (en) 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
IE802177L (en) 1980-10-21 1981-05-12 Takeda Chemical Industries Ltd Imidazol-5-ylacetic acid derivatives
JPS58157768A (ja) 1982-03-16 1983-09-19 Takeda Chem Ind Ltd 4−クロロ−2−フエニルイミダゾ−ル−5−酢酸誘導体
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US4820843A (en) 1987-05-22 1989-04-11 E. I. Du Pont De Nemours And Company Tetrazole intermediates to antihypertensive compounds
US5015651A (en) 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
US4880804A (en) 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
CA1338238C (en) 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US4898732A (en) * 1988-05-04 1990-02-06 The Clinipad Corporation Inhibiting of tumor growth with an antagonist of the renin-angioten-sin system
DE3928177A1 (de) 1989-04-08 1991-02-28 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
IE64514B1 (en) 1989-05-23 1995-08-09 Zeneca Ltd Azaindenes
DE69010076T2 (de) * 1989-05-25 1994-12-08 Takeda Chemical Industries Ltd Transdermales therapeutisches Mittel.
CA2018443A1 (en) 1989-06-14 1990-12-14 Joseph A. Finkelstein Imidazolyl-alkenoic acids
RU2099330C1 (ru) 1989-06-30 1997-12-20 Е.И.Дюпон Де Немур Энд Компани Замещенные имидазолы или их фармацевтически приемлемые соли и фармацевтическая композиция
CA2020073A1 (en) 1989-07-03 1991-01-04 Eric E. Allen Substituted quinazolinones as angiotensin ii antagonists
EP0407342A3 (en) 1989-07-06 1991-07-10 Ciba-Geigy Ag Pyrimidine derivatives
EP0409332A3 (en) 1989-07-19 1991-08-07 Merck & Co. Inc. Substituted triazoles as angiotensin ii antagonists
US5225205A (en) * 1989-07-28 1993-07-06 Debiopharm S.A. Pharmaceutical composition in the form of microparticles
EP0411507B1 (en) 1989-08-02 1994-10-26 Takeda Chemical Industries, Ltd. Pyrazole derivatives, their production and use
IL95975A (en) 1989-10-24 1997-06-10 Takeda Chemical Industries Ltd N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
EP0434038A1 (en) 1989-12-22 1991-06-26 Takeda Chemical Industries, Ltd. Fused imidazole derivatives, their production and use
DE69129998T2 (de) 1990-02-15 1998-12-24 Takeda Chemical Industries, Ltd., Osaka Pyrimidindionderivate, deren Herstellung und Verwendung
CA2036618C (en) * 1990-02-22 2002-10-29 Akira Morimoto Fused thiophene derivatives, their production and use
IE912956A1 (en) * 1990-09-10 1992-03-11 Abbott Lab Angiotensin ii receptor antagonists
US5171217A (en) * 1991-02-28 1992-12-15 Indiana University Foundation Method for delivery of smooth muscle cell inhibitors
TW274551B (no) 1991-04-16 1996-04-21 Takeda Pharm Industry Co Ltd
CZ36394A3 (en) * 1991-08-19 1994-07-13 Du Pont Substituted imidazilonone derivatives and pharmaceutical preparations based thereon
TW284688B (no) * 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
US5656297A (en) 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
GB2272899A (en) * 1992-11-30 1994-06-01 Du Pont Merck Pharma Angiotensin-11 receptor blocking cycloalkylbenzylimidazoles
EP0603712B1 (en) 1992-12-22 2001-08-16 Takeda Chemical Industries, Ltd. Heterocyclic compounds having angiotensin II antagonistic activity and use thereof
US5288720A (en) * 1993-04-23 1994-02-22 American Cyanamid Company Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
KR101222904B1 (ko) * 1993-07-19 2013-01-17 안지오테크 파마슈티칼즈, 인코포레이티드 항맥관형성 조성물, 당해 조성물로 피복된 스텐트 및 당해 스텐트의 제조방법
JPH0789849A (ja) 1993-09-20 1995-04-04 Fujisawa Pharmaceut Co Ltd 徐放性製剤
CA2224381A1 (en) * 1995-06-27 1997-01-16 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
DK0889880T3 (da) 1996-03-29 2003-09-01 Smithkline Beecham Corp Eprosartan-dihydrat og fremgangsmåde til fremstilling deraf samt formulering
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US6201002B1 (en) * 1997-01-10 2001-03-13 Merck & Co., Inc. Method for reducing mortality with an angiotensin II antagonist
US5958884A (en) * 1997-04-11 1999-09-28 The Brigham And Women's Hospital, Inc. Compositions and methods for treating erectile dysfunction
US6306826B1 (en) * 1997-06-04 2001-10-23 The Regents Of The University Of California Treatment of heart failure with growth hormone
DE19741635A1 (de) * 1997-09-22 1999-03-25 Hoechst Marion Roussel De Gmbh Biphenylsulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
IL137979A0 (en) * 1998-03-04 2001-10-31 Takeda Chemical Industries Ltd Production, release preparation for aii antagonist-sustained and use thereof

Also Published As

Publication number Publication date
BR9908474A (pt) 2000-12-05
LT4800B (lt) 2001-06-25
SK11902000A3 (sk) 2001-02-12
NO20004350L (no) 2000-10-03
LV12585B (en) 2001-03-20
EP1058541B1 (en) 2004-01-28
ZA991706B (en) 2000-10-03
CA2318446A1 (en) 1999-09-10
US7294344B2 (en) 2007-11-13
EE200000499A (et) 2002-02-15
EP1058541A1 (en) 2000-12-13
US6589547B1 (en) 2003-07-08
ATE258430T1 (de) 2004-02-15
CA2318446C (en) 2008-09-23
HUP0101439A3 (en) 2002-09-30
US20030198676A1 (en) 2003-10-23
CN1291888A (zh) 2001-04-18
AU2745199A (en) 1999-09-20
DE69914460T2 (de) 2004-10-28
PL342684A1 (en) 2001-07-02
WO1999044590A1 (en) 1999-09-10
DE69914460D1 (de) 2004-03-04
KR20010086245A (ko) 2001-09-10
LV12585A (en) 2000-12-20
IL137979A0 (en) 2001-10-31
HUP0101439A2 (hu) 2001-10-28
ES2214013T3 (es) 2004-09-01
LT2000082A (en) 2001-03-26
ID25640A (id) 2000-10-19

Similar Documents

Publication Publication Date Title
NO20004350D0 (no) Preparat med vedvarende frigivinng av AII-antagonist, fremstilling og anvendelse herav
DE60119397D1 (de) "2-Oxo-1-Pyrrolidinderivate und ihre pharmazeutische Verwendung"
DE69926806D1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
DE69926919D1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
DE60124684D1 (de) Sulfonamido-substituierte verbrückte bicycloalkylderivative
EA200301165A1 (ru) Лекарственное средство на основе оксикодона
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
BG66085B1 (bg) Фенилаланинови производни
ATE425139T1 (de) Benzamidinderivate
DE60121461D1 (de) Kondensierte pyridoindolderivate
EA200200742A1 (ru) 1,2-диарилбензимидазолы для лечения заболеваний, связанных с активацией микроглии
EA200001061A1 (ru) Фармацевтическая композиция
HRPK20040372B3 (en) Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist
HRP20080521T3 (en) Orodispersible pharmaceutical composition of an antithrombotic compound
ATE326451T1 (de) Chinazolin derivate und therapeutische verwendungen davon
DE60028928D1 (de) Verwendung von angiotensin ii rezeptorantagonisten zur behandlung von akutem myokardischen infarkt
NO20001548L (no) Endotelinantagonist og en renin-angiotensinsystem inhibitor som et kombinert preparat
BR0000486A (pt) Antagonistas do neuropeptìdeo y
RS51316B (sr) Nova upotreba (r)-(-)-2-/5-(4-fluorofenil)-3- piridilmetilaminometil/-hromana i njegovih fiziološki prihvatljivih soli
ATE403644T1 (de) Amidinophenylbrenztraubensäure-derivat
EA200401617A1 (ru) Комбинация nmda-антагониста и ингибиторов ацетилхолинэстеразы для лечения болезни альцгеймера
TH63279A (th) สารประกอบที่ปรับฤทธิ์ ppar